Wednesday’s total option volume of 46.9 million contracts resulted in net open interest growth of 5.42 million calls and 4.48 million puts.
Intellia Therapeutics (NTLA) announced the first patient has been dosed in MAGNITUDE-2, a global, pivotal Phase 3 trial of nexiguran ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback